Siga Technologies, Inc. (SIGA), Tuesday announced that it entered into an agreement with Vanderbilt University in Nashville, Tennessee to obtain license for a portfolio of preclinical fully human monoclonal antibodies as a potential treatment for a broad range of orthopoxviruses, including smallpox and mpox.
The financial terms of the transaction were not disclosed. Under the agreement, Siga, a commercial-stage pharmaceutical company, has exercised its option to license the exclusive rights for the antibodies globally.
These monoclonal antibodies is expected to have potential to be used as standalone treatments or in combination with TPOXX.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.